Using intravenous topiramate to treat severe seizures that don't respond to other medications.
Treatment of status epilepticus and refractory status epilepticus with intravenous topiramate.
This study is looking at how well intravenous topiramate can help people with severe seizures that don’t respond to regular treatments, hoping to offer a better option for those in need.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Prevep, INC. NIH-funded |
| Lab location | 1 site (Bethesda, United States) |
| Project ID | NIH-10932890 on NIH RePORTER |
What this research studies
This research focuses on treating status epilepticus (SE) and refractory status epilepticus (RSE), which are serious neurological emergencies that often do not respond to standard anti-seizure medications. The study aims to evaluate the effectiveness of intravenous topiramate, a medication that has shown promise in previous cases of treatment-resistant seizures. By administering topiramate intravenously, the researchers hope to provide a more effective option for patients experiencing severe seizures. The approach is based on the medication's unique mechanism of action and its potential neuroprotective benefits.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals experiencing status epilepticus or refractory status epilepticus who have not responded to first- and second-line anti-seizure medications.
Not a fit: Patients who do not have status epilepticus or refractory status epilepticus may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients suffering from severe and treatment-resistant seizures.
How similar studies have performed: Previous research has indicated that intravenous topiramate may be effective in treating highly resistant seizures, suggesting potential success for this approach.
Where this research is happening
Bethesda, United States
- Prevep, INC. — Bethesda, United States (Active)
Researchers
- Principal investigator: Klein, Pavel — Prevep, INC.
- Study coordinator: Klein, Pavel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.